Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of the rhythmic changes in the proteome of different subtypes of pancreatic ductal adenocarcinoma

ABSTRACT: At present, there is no reliable biomarker for the diagnosis of pancreatic ductal adenocarcinoma (PDAC). Due to this, together with the asymptomatic nature of the cancer, PDAC is often diagnosed at an advanced stage with an abysmal 5-year survival rate. Hence, a reliable biomarker for the timely diagnosis of PDAC is essential. The altered levels of protein expression are one of the hallmarks of cancer. Understanding these changes in PDAC could yield insights into the development of the disease and hence could potentially identify new biomarkers. Hence, in this study, mass spectrometry-based label‐free quantitative proteomics was employed to investigate the differently expressed proteins in the pancreatic cancer cell lines (Capan-2 and PANC-1), benign pancreatic cells (hTERT-HPNE) and normal pancreatic duct epithelial cells (H6c7). Furthermore, to study the circadian variations in the secretome of the pancreatic cell lines, the rhythmic expression of proteins was investigated at 6-hour intervals over 24 hours. The findings of this study provide novel insights into the processes and pathways involved in PDAC, potentially leading to the identification of circadian-based subtype-specific biomarkers.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Pancreatic Ductal Adenocarcinoma

SUBMITTER: Jaime Jayapalan

LAB HEAD: Dr. Jaime Jacqueline Jayapalan

PROVIDER: PXD054693 | Pride | 2026-02-23

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	0H_txt.zip	Other
	12H_txt.zip	Other
	18H_txt.zip	Other
	6H_txt.zip	Other
	Capan2_0H_040124_R1.raw	Raw

Items per page:

1 - 5 of 56

Similar Datasets

Label-free quantitative proteomics analysis of Drosophila melanogaster lethal giant larvae mutants reveals potential therapeutic effects of melatonin

Project description:The present study is a pioneering investigation that has been carefully designed to study proteomic effects of specific cancer-related mutation using the lgl mutant of D. melanogaster that has not been well characterised thus far. Recent findings concerning the D. melanogaster cancer models suggest that this model is well suited for study of cancer mechanisms and therapeutic interventions, especially in the brain and intestines (Mirzoyan et al., 2019). In addition, the integration of circadian biology into cancer research offers new insights into the implications of optimal timing for cancer treatment that could potentially reduce undesirable side effects and enhance prognosis (Ballesta et al., 2017). As a result, label free quantitative mass spectrometry was employed to investigate tissue-specific protein expression in head and intestinal tissues of D. melanogaster lgl mutants which was collected at 6-hours intervals throughout the 24-hour period. Furthermore, the efficacy of melatonin as an anticancer agent at the proteome level was also investigated. Together, the resulting information could potentially identify malfunctioning signalling pathways and circadian rhythm-dependent protein markers during tumorigenesis, as well as the mechanism of actions of melatonin on these processes, post-treatment

2023-05-10 | PXD033191 | Pride

mRNA Expression profiles of parental Panc cell lines and Gemcitabine resistance Panc1cell lines

Project description:Gemcitabine (GEM) is a key drug for treating PDAC, and it is commonly used for adjuvant chemotherapy. Although the majority of PDAC is sensitive to GEM at first, GEM cannot control PDAC for very long, suggesting that PDAC develops resistance to GEM after prolonged exposure. No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma. This study assesses gemcitabine resistant PDAC for its specific mRNA expression pattern. Gemcitabine resistant variants of Panc1, a human pancreatic adenocarcinoma cell line, were established. mRNA screening was investigated by microarray.

2016-04-26 | GSE80617 | GEO

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant ChemotherapyIdentification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

Project description:Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront surgery. Hence, there is an unmet need for accurate biomarkers for predicting NAC response in PDAC. This project aimed to identify upregulated proteins in tumor tissue from poor- and good-NAC responders.

2020-04-16 | PXD017051 | Pride

Microarray Expression Analysis of Circular RNAs in Pancreatic Ductal Adenocarcinoma

Project description:To investigate the expression profile of circular RNAs (circRNAs) in pancreatic ductal adenocarcinoma(PDAC) and to provide more reliable biomarkers and new potential diagnostic and therapeutic targets for PDAC. The circRNA expression levels were measured in 20 paracancerous tissues and 20 PDAC tissues using Arraystar Human CircRNA Array Analysis. We identified significantly different expression of circRNAs between the two groups and showed distinguishable circRNAs expression patterns in the samples. The levels and patterns of circRNA expression were significantly different between paracancerous tissue and PDAC tissue. This study evaluated circRNAs expression profiles and their ability to serve as reliable biomarkers and new potential diagnostic and therapeutic targets for PDAC.

2016-10-07 | GSE79634 | GEO

Microarray Expression Analysis of Circular RNAs in Pancreatic Ductal Adenocarcinoma

Project description:To investigate the expression profile of circular RNAs (circRNAs) in pancreatic ductal adenocarcinoma(PDAC) and to provide more reliable biomarkers and new potential diagnostic and therapeutic targets for PDAC. The circRNA expression levels were measured in 3 paracancerous tissues and 3 PDAC tissues using Arraystar Human CircRNA Array Analysis. We identified significantly different expression of circRNAs between the two groups and showed distinguishable circRNAs expression patterns in the samples. The levels and patterns of circRNA expression were significantly different between paracancerous tissue and PDAC tissue. This study evaluated circRNAs expression profiles and their ability to serve as reliable biomarkers and new potential diagnostic and therapeutic targets for PDAC.

2025-03-05 | GSE289888 | GEO

microRNA Expression profiles of parental Panc1 cell lines and Gemcitabine resistance Panc1 cell lines

Project description:Gemcitabine (GEM) is a key drug for treating PDAC, and it is commonly used for adjuvant chemotherapy. Although the majority of PDAC is sensitive to GEM at first, GEM cannot control PDAC for very long, suggesting that PDAC develops resistance to GEM after prolonged exposure. No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma. MicroRNAs (miR) are epigenetic gene regulators with tumorsuppressive or oncogenic roles in various carcinomas. This study assesses gemcitabine resistant PDAC for its specific miR expression pattern. Gemcitabine resistant variants of Panc1, a human pancreatic adenocarcinoma cell line, were established. MicroRNA screening was investigated by microarray.

2016-04-26 | GSE80616 | GEO

Effect of depletion of HMOX1 on gene expression of AsPC-1 cells.

Project description:Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors. Endoplasmic reticulum stress plays an essential role in PDAC progression. Here, we aim to identify the ERS-related genes in PDAC and build reliable risk models for diagnosis, prognosis and immunotherapy response of PDAC patients. We report HMOX1 as an important gene of ER stress related-signature we established in PDAC. The depletion of HMOX1 results in tumor growth inhibition. Our data lay the foundation for further investigating the potential mechanism.

2023-08-24 | GSE241352 | GEO

TNFα-producing Macrophages Determine Subtype Identity and Prognosis via AP1 Enhancer Reprogramming in Pancreatic Cancer [TNFa-treatment RNA-seq]

Project description:In pancreatic cancer, classical and basal-like subtypes are identified as two major PDAC subtypes. Our previous data showed that PDAC tumor cells can switch between the two phenotypes through transcriptional reprogramming particularly in response to inflammatory cues. In this study, we were trying to understand TNFα mediated transcription regulatory network in pancreatic cancer. Hence, we performed RNA-seq in TNFα treated classical cells as well as aqua dest control.

2021-07-02 | GSE152830 | GEO

MicroRNA screening in human pancreatic carcinoma cell lines

Project description:No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma. MicroRNAs (miR) are epigenetic gene regulators with tumorsuppressive or oncogenic roles in various carcinomas. This study assesses chemoresistant PDAC for its specific miR expression pattern. Gemcitabine-resistant variants of two mutant p53 human pancreatic adenocarcinoma cell lines were established. MicroRNA screening was investigated by microarray.

2015-11-03 | GSE74565 | GEO

In vitro microRNA screening in human pancreatic adenocarcinoma

Project description:No reliable predictors of susceptibility to gemcitabine chemotherapy exist in pancreatic ductal adenocarcinoma. MicroRNAs (miR) are epigenetic gene regulators with tumorsuppressive or oncogenic roles in various carcinomas. This study assesses chemoresistant PDAC for its specific miR expression pattern. Gemcitabine-resistant variants of PANC-1, a mutant p53 human pancreatic adenocarcinoma cell line, were established. MicroRNA screening was investigated by microarray.

2015-11-03 | GSE74562 | GEO